Continued access to deucravacitinib for past study participants
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study gives continued access to the study drug deucravacitinib for people who completed previous trials for lupus, Sjogren's disease, psoriasis, or psoriatic arthritis. It helps you keep receiving the treatment after your original study ends.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed one of the listed parent studies for the full treatment period.
- It must be safe for you to continue the study drug, according to the study doctor.
- You are an adult who took part in a qualifying study for SLE or Sjogren's disease, or a child/adolescent who took part in a qualifying psoriasis or psoriatic arthritis study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study looks at how well deucravacitinib works for people with moderate to severe plaque psoriasis in real-life settings in Italy. It follows patients who have already started the treatment to see how they are doing.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
This program provides early access to upadacitinib, a medication that may help treat your condition when other options are not suitable. It is designed for patients who cannot join a clinical trial but have no other treatment choices.
This study lets people who have already finished a previous trial of deucravacitinib continue taking the medicine. It is for adults with lupus, including skin-only forms of the disease, to see if long-term treatment remains safe and helpful.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.